Protease inhibitors such as AbbVie’s HIV drug Kaletra (lopinavir/ritonavir) and Ascletis Pharma’s HCV therapy Ganovo (danoprevir) evoke suspicion for their potential in Covid-19, as there is a low probability of an inhibitor being efficient against two separate viruses with distinct structures.
In March, AbbVie said there were unconfirmed media reports that information from China showed Kaletra’s efficacy in Covid-19 but that it did not have access to that data. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
